Arrowhead Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ARWR and other ETFs, options, and stocks.

About ARWR

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. 

CEO
Christopher Richard Anzalone
CEOChristopher Richard Anzalone
Employees
711
Employees711
Headquarters
Pasadena, California
HeadquartersPasadena, California
Founded
1989
Founded1989
Employees
711
Employees711

ARWR Key Statistics

Market cap
8.34B
Market cap8.34B
Price-Earnings ratio
-914.29
Price-Earnings ratio-914.29
Dividend yield
Dividend yield
Average volume
3.74M
Average volume3.74M
High today
$67.60
High today$67.60
Low today
$60.30
Low today$60.30
Open price
$63.22
Open price$63.22
Volume
3.44M
Volume3.44M
52 Week high
$67.60
52 Week high$67.60
52 Week low
$9.57
52 Week low$9.57

Stock Snapshot

With a market cap of 8.34B, Arrowhead Pharmaceuticals(ARWR) trades at $61.44. The stock has a price-to-earnings ratio of -914.29.

As of 2025-12-07, Arrowhead Pharmaceuticals(ARWR) stock has fluctuated between $60.30 and $67.60. The current price stands at $61.44, placing the stock +1.9% above today's low and -9.1% off the high.

Arrowhead Pharmaceuticals(ARWR) shares are trading with a volume of 3.44M, against a daily average of 3.74M.

In the last year, Arrowhead Pharmaceuticals(ARWR) shares hit a 52-week high of $67.60 and a 52-week low of $9.57.

In the last year, Arrowhead Pharmaceuticals(ARWR) shares hit a 52-week high of $67.60 and a 52-week low of $9.57.

ARWR News

Simply Wall St 2d
Arrowhead Pharmaceuticals Valuation After FDA Breakthrough Therapy Designation for Plozasiran

Arrowhead Pharmaceuticals (ARWR) just got a meaningful regulatory boost, with the FDA granting Breakthrough Therapy designation to its triglyceride lowering dru...

Arrowhead Pharmaceuticals Valuation After FDA Breakthrough Therapy Designation for Plozasiran
Simply Wall St 5d
Have Arrowhead Pharmaceuticals Insiders Been Selling Stock?

We'd be surprised if Arrowhead Pharmaceuticals, Inc. ( ) shareholders haven't noticed that the Independent Director, Mauro Ferrari, recently sold US$493k worth...

Have Arrowhead Pharmaceuticals Insiders Been Selling Stock?
Simply Wall St 7d
Arrowhead Pharmaceuticals Is Up 19.1% After FDA Approval of First siRNA Therapy for FCS

Arrowhead Pharmaceuticals recently announced U.S. FDA approval for REDEMPLO (plozasiran), its first siRNA medicine for reducing triglycerides in adults with fam...

Arrowhead Pharmaceuticals Is Up 19.1% After FDA Approval of First siRNA Therapy for FCS

Analyst ratings

64%

of 14 ratings
Buy
64.3%
Hold
35.7%
Sell
0%

People also own

Based on the portfolios of people who own ARWR. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.